Supplemental Figure 10 shows immunoblotting of FLT-3 signaling pathway in quizartinib-resistant AML PDX models.
No takes yet. Share an insight, caveat, or question.
Olesinski et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: